Agilent Reports Q1 2026 EPS of $1.07, Down 10% Year-Over-Year

Agilent Technologies (NYSE: A) reported first-quarter fiscal 2026 earnings that showed continued pressure on the life sciences equipment sector, with earnings per share of $1.07 for the quarter ended January 31, 2026.

Key Numbers

The company's reported EPS of $1.07 for Q1 2026 represents a notable decline from the $1.18 reported in Q3 2025, suggesting momentum has slowed entering the new fiscal year. This marks a sequential decline of approximately 9.3% from the most recent quarterly comparison.

Net income for the quarter came in at $300 million, compared to $340 million in Q3 2025, reflecting a decline of nearly 12% on a sequential basis. This compares to the full fiscal year 2025 net income of $1.30 billion, which averaged approximately $325 million per quarter.

The earnings trajectory shows a marked deceleration from fiscal 2025's full-year EPS of $4.57. If the current quarterly run rate continues, Agilent would be on track for annual EPS of approximately $4.28, representing a potential 6.3% decline year-over-year.

Historical revenue data shows the company generated $4.47 billion in fiscal 2017, up from $4.20 billion in fiscal 2016 and $4.04 billion in fiscal 2015, demonstrating the company's longer-term growth trajectory before recent headwinds emerged.

What Management Said

While the 8-K filing did not include detailed management commentary or guidance updates, the company indicated it would provide non-GAAP financial information to offer "meaningful supplemental information regarding its operational performance." Management emphasized their focus on providing transparency through metrics that facilitate internal comparisons to historical operating results and competitor performance.

The filing notes that management uses non-GAAP measures to assess segment and enterprise performance, excluding items such as restructuring and amortization charges that may have material effects on reported expenses and earnings per share. This suggests the company continues to work through operational adjustments that are impacting reported results.

Management stated they monitor these excluded items "to ensure that expenses are in line with expectations" but do not use them to measure ongoing operating performance, indicating a focus on core business metrics rather than one-time charges.

What to Watch

Several key factors merit attention in upcoming quarters. The sequential decline in both EPS and net income suggests Agilent may be experiencing continued softness in demand for life sciences and diagnostics equipment, a trend that has affected multiple companies in the sector throughout 2025.

The gap between Q1 performance and the fiscal 2025 average raises questions about whether this represents seasonal weakness typical of Agilent's first quarter or signals a more sustained downturn. Investors should monitor whether the company can return to sequential growth in Q2 2026.

The company's emphasis on non-GAAP reporting and exclusion of restructuring charges suggests ongoing operational changes that could either position the company for improved profitability once complete or continue to weigh on near-term results. The magnitude and duration of these adjustments will be important to track.

Given the 9.3% sequential EPS decline, attention should focus on whether Agilent maintains, reduces, or withdraws fiscal 2026 guidance in upcoming communications. Any commentary on end-market conditions, particularly in pharmaceutical and biotechnology customer segments, will provide crucial context for the earnings trajectory.

The life sciences tools sector has faced inventory normalization and budget constraints at customer organizations throughout 2025. Agilent's results suggest these headwinds persist into 2026, making any signs of stabilization or improvement in order patterns a key indicator for potential recovery.

With net income declining more steeply than the historical growth trajectory would suggest, margin pressure appears evident. Investors should watch for management's strategy to defend profitability, whether through cost reduction initiatives, portfolio optimization, or strategic pricing actions.

*Source: SEC Form 8-K filed February 25, 2026*

*StockCliff Research*